Site icon pharmaceutical daily

Macrogen and Exosome Plus to Jointly Develop Exosome-based Diagnostic and Treatment Solutions

BusinessWire

SEOUL, South Korea–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/Exosome?src=hash” target=”_blank”gt;#Exosomelt;/agt;–The precision medicine and biotechnology company Macrogen
(CEO Kap-Seok Yang, www.macrogen.com/en/)
announced on April 24 that it had signed a supply contract with Exosome
Plus (CEO Jong-Uk Bu, www.exosomeplus.com)
on April 19 to become the exclusive buyer of the exosome isolation kits
developed by Exosome Plus. The two companies also signed an MOU for the
joint development of exosome-based diagnostic and treatment solutions.

Under the newly signed contract, Exosome Plus will exclusively supply
its high-efficiency exosome isolation kit ‘Exo2DTM’ to
Macrogen for one year. Also, according to the contract, Macrogen may
sell the isolation kits to third parties.

Macrogen will use the isolation kits for its ‘exosomal RNA and DNA
sequencing service’ a new high added value product that Macrogen offers
to the research market. The use of the isolation kits is expected to
improve production efficiency and service stability. Macrogen also plans
to sell the isolation kits across its domestic and global distribution
network, creating additional profits.

In addition to the supply contract, the two companies also signed an MOU
for mutual collaboration., Under the MOU, both companies agreed to work
together closely for R&D and business development in the areas of
exosome-based disease diagnosis and treatment. Specifically, the MOU
covers: the development of exosome-based biomarkers for early diagnosis;
the development of therapeutic agents; applied uses such as drug
delivery carriers, vaccines, and cosmetics; cooperative education and
training to foster the manpower necessary for the development of
pharmaceuticals; and the joint use of infrastructure, including
equipment and facilities.

Jong-Uk Bu, CEO of Exosome Plus, commented “Macrogen is a leader of the
Korean exosomes market, with more than 1,000 different experiences
analyzing exosomal RNA and DNA. The company has the technical expertise
needed to provide high-quality nucleic acid analysis results using only
trace amounts of exosomes.” He added, “Bringing together Exosome Plus
high-purity exosome isolation technology and Macrogen’s NGS analysis
expertise will allow us to provide domestic and international
researchers with more accurate and efficient services.”

Kap-Seok Yang, CEO of Macrogen, remarked, “Exosomes are an industry with
huge potential, and their use is expanding rapidly into fields such as
disease diagnosis and treatment, pharmaceuticals, and more.” He went on
to say, “By strengthening our cooperative relations with Exosome Plus, a
company which boasts unrivaled competitive power in the fields of
exosome isolation and quality control—considered the greatest technical
hurdles to exosome research—we will be able to begin our efforts in
earnest to enter the exosome-based biopharmaceuticals market.”

Macrogen and Exosome Plus will also be participating in the 2019 meeting
of the International Society for Extracellular Vesicles (ISEV) to be
held in Kyoto, Japan from April 25 to 28. At the conference, the two
companies will jointly present their exosome isolation and nucleic acid
analysis technologies. Starting with the ISEV meeting, Macrogen and
Exosome Plus will actively engage in joint marketing for the development
of domestic and overseas markets.

According to the market research organization Grand
View Research, based in the USA, the global exosome market is
expected to grow to approximately USD 2.28 billion by 2030.

Contacts

Contact us for Service
ngskr@macrogen.com

Contact us for the press release
Macrogen Inc.
Mikyung
Kim, +82-2-2180-7026
pr@macrogen.com

Exit mobile version